CoChat
Sign Up
Cited by 123Alzheimer's disease research and treatmentsCannabis and Cannabinoid ResearchMedicinal Plants and Neuroprotection

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

The potential therapeutic effects of THC on Alzheimer’s disease

Cao, Chuanhai, Li, Yaqiong, Liu, Hui, Bai, Ge, Mayl, Jonathan, Lin, Xiaoyang, Sutherland, Kyle, Nabar, Neel, Cai, Jianfeng·2014·Journal of Alzheimer s Disease
DOI 10.3233/jad-140093
Open this paper in CoChat — free account

Abstract

The purpose of this study was to investigate the potential therapeutic qualities of Δ9-tetrahydrocannabinol (THC) with respect to slowing or halting the hallmark characteristics of Alzheimer's disease. N2a-variant amyloid-β protein precursor (AβPP) cells were incubated with THC and assayed for amyloid-β (Aβ) levels at the 6-, 24-, and 48-hour time marks. THC was also tested for synergy with caffeine, in respect to the reduction of the Aβ level in N2a/AβPPswe cells. THC was also tested to determine if multiple treatments were beneficial. The MTT assay was performed to test the toxicity of THC. Thioflavin T assays and western blots were performed to test the direct anti-Aβ aggregation significance of THC. Lastly, THC was tested to determine its effects on glycogen synthase kinase-3β (GSK-3β) and related signaling pathways. From the results, we have discovered THC to be effective at lowering Aβ levels in N2a/AβPPswe cells at extremely low concentrations in a dose-dependent manner. However, no additive effect was found by combining caffeine and THC together. We did discover that THC directly interacts with Aβ peptide, thereby inhibiting aggregation. Furthermore, THC was effective at lowering both total GSK-3β levels and phosphorylated GSK-3β in a dose-dependent manner at low concentrations. At the treatment concentrations, no toxicity was observed and the CB1 receptor was not significantly upregulated. Additionally, low doses of THC can enhance mitochondria function and does not inhibit melatonin's enhancement of mitochondria function. These sets of data strongly suggest that THC could be a potential therapeutic treatment option for Alzheimer's disease through multiple functions and pathways.

Overview

Integrity signals

Registry

Crossref · 10.3233/jad-140093

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 42 references

Cited by

Sorted by citations

Items 101–123 of 123

Related

See all

Metadata

Authors
Cao, C., Li, Y., Liu, H., Bai, G., Mayl, J., Lin, X., Sutherland, K., Nabar, N., & Cai, J.
Affiliations
  • University of South Florida (US)
  • Thomas Jefferson University (US)
ORCID
Venue
Journal of Alzheimer s Disease
Publisher
SAGE Publications
Published
2014-09-16
Volume
42
Issue
3
Pages
973-984
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
DOI
10.3233/jad-140093
OpenAlex
W2132194615
Cited by
121
References
42
Citations by year
2026: 6 · 2025: 10 · 2024: 6 · 2023: 14 · 2022: 27 · 2021: 11 · 2020: 11 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 6 · 2014: 2
FWCI
5.10
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
Keywords
delta-9-tetrahydrocannabinol, Alzheimer's disease
MeSH terms
Glycogen Synthase Kinase 3 beta, Animals, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Humans, Mitochondria, Mutation, Neuroblastoma, Phosphorylation, Dronabinol, Transfection, Signal Transduction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Cell Respiration, Glycogen Synthase Kinase 3, Cell Line, Tumor, Mice, Cannabinoid Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review